Division of Bioethics and Healthcare Law, The Institute for Cancer Control, The National Cancer Center Japan, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.
Office of Bioethics, The Center for Clinical Sciences, The National Center for Global Health and Medicine, Tokyo, Japan.
BMC Med Ethics. 2021 Dec 25;22(1):168. doi: 10.1186/s12910-021-00738-9.
Whether and how to disclose genomic findings obtained in the course of genomic clinical practice and medical research has been a controversial global bioethical issue over the past two decades. Although several recommendations and judgment tools for the disclosure of genomic findings have been proposed, none are sufficiently systematic or inclusive or even consistent with each other. In order to approach the disclosure/non-disclosure practice in an ethical manner, optimal and easy-to-use tools for supporting the judgment of physicians/researchers in genomic medicine are necessary.
The bioethics literature on this topic was analyzed to parse and deconstruct the somewhat overlapping and therefore ill-defined key concepts of genomic findings, such as incidental, primary, secondary, and other findings. Based on the deconstruction and conceptual analyses of these findings, we then defined key parameters from which to identify the strength of duty to disclose (SDD) for a genomic finding. These analyses were then applied to develop a framework with the SDD matrix and systematic decision-making pathways for the disclosure of genomic findings.
The following six major parameters (axes), along with sub-axes, were identified: Axis 1 (settings and institutions where findings emerge); Axis 2 (presence or absence of intention and anticipatability in discovery); Axis 3 (maximal actionability at the time of discovery); Axis 4 (net medical importance); Axis 5 (expertise of treating physician/researcher); and Axis 6 (preferences of individual patients/research subjects for disclosure). For Axes 1 to 4, a colored SDD matrix for genomic findings was developed in which levels of obligation for disclosing a finding can be categorized. For Axes 5 and 6, systematic decision-making pathways were developed via the SDD matrix.
We analyzed the SDD of genomic findings and developed subsequent systematic decision-making pathways of whether and how to disclose genomic findings to patients/research subjects and their relatives in an ethical manner. Our comprehensive framework may help physicians and researchers in genomic medicine make consistent ethical judgments regarding the disclosure of genomic findings.
在过去的二十年中,在基因组临床实践和医学研究过程中是否以及如何披露基因组发现一直是一个备受争议的全球生物伦理问题。尽管已经提出了一些关于基因组发现披露的建议和判断工具,但没有一个是足够系统或全面的,甚至彼此之间也不一致。为了以合乎道德的方式处理披露/不披露的做法,有必要为从事基因组医学的医生/研究人员提供最佳和易于使用的工具来支持他们的判断。
对该主题的生物伦理学文献进行了分析,以解析和分解基因组发现的一些重叠且因此定义不明确的关键概念,例如偶然发现、主要发现、次要发现和其他发现。基于对这些发现的解构和概念分析,然后我们定义了关键参数,用于确定基因组发现披露的义务强度(SDD)。然后,这些分析被应用于开发一个具有 SDD 矩阵和系统决策途径的框架,用于披露基因组发现。
确定了以下六个主要参数(轴)及其子轴:轴 1(发现结果出现的环境和机构);轴 2(发现时是否存在意图和可预测性);轴 3(发现时最大的可操作性);轴 4(净医学重要性);轴 5(治疗医生/研究人员的专业知识);和轴 6(个体患者/研究对象对披露的偏好)。对于轴 1 到 4,我们开发了一个彩色 SDD 矩阵,用于对基因组发现的义务程度进行分类。对于轴 5 和 6,通过 SDD 矩阵开发了系统决策途径。
我们分析了基因组发现的 SDD,并开发了随后的系统决策途径,以伦理的方式向患者/研究对象及其亲属披露基因组发现。我们的综合框架可以帮助从事基因组医学的医生和研究人员对披露基因组发现做出一致的伦理判断。